Business Context and Reporting Period
Company: Repro-Med Systems, Inc. (Note: Metadata referenced "KORU Medical Systems," but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: May 31, 2011
Business Overview: The Company researches, develops, manufactures, and markets medical devices, primarily the Freedom60® Syringe Infusion Pump and the RES-Q-VAC® Portable Medical Suction System. It is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended May 31, 2011 | Three Months Ended May 31, 2010 |
|---|---|---|
| Net Sales | $1,493,970 | $982,942 |
| Gross Profit | $953,785 | $619,554 |
| Gross Margin | 63.8% | 63.0% |
| Net Operating Profit | $331,961 | $136,039 |
| Net Income | $197,959 | $88,420 |
| Net Cash from Operating Activities | $346,619 | $288,983 |
| Cash and Cash Equivalents (End of Period) | $1,627,406 | $1,054,416 |
| Total Debt (Current + Long-Term) | $513,736 | $523,739 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 52% year-over-year, driven primarily by a 54% increase in Freedom60® sales, which accounted for 84% of total revenue in the current quarter.
- Profitability: Net operating profit increased 144% and Net Income increased 123.9% compared to the prior year quarter.
- Expense Management: Selling, General, and Administrative (SG&A) expenses rose 27.3% due to marketing and new product development, but SG&A as a percentage of net sales improved to 39.3% from 46.9%.
- Cost of Goods Sold (COGS): COGS increased 48.7% in line with higher production volumes; however, gross margin expanded slightly to 63.8%.
- Interest Expense: Decreased 26.7% due to the repayment of a shareholder note in June 2010.
Outlook, Management Commentary, and Risks
Management Commentary and Outlook
- Liquidity: Management states that increased sales and cash flow, combined with current capital, are sufficient to meet liquidity needs for the next twelve months.
- New Product Launch: The Company received FDA approval on May 20, 2011, for the High-Flo® RMS Subcutaneous Needle Set for domestic marketing. The Company is expanding staff and inventory to meet anticipated demand.
- Market Expansion: The Company is actively pursuing the hospital market for RES-Q-VAC® and expanding Freedom60® applications to include antibiotics (e.g., Vancomycin) and pain control.
- Reimbursement: A new Medicare HCPCS code (E0779) has been secured, significantly increasing reimbursement rates for the Freedom60® system.
Risks and Contingencies
- Regulatory Dependence: Future results depend on FDA approvals and the continued availability of favorable Medicare reimbursement codes.
- Competition: The Company faces competition from larger entities with more resources (e.g., Laerdal, Ambu) and potential new market entrants.
- Market Acceptance: There is no assurance that the domestic market will adopt the new High-Flo® needle sets or that competitors will not introduce superior products.
- Key Personnel: Operations depend on the continued service of key personnel.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of Freedom60® sales, which represented 84% of total revenue in Q1 2011.
- Reimbursement Stability: Confirm the long-term viability of the new Medicare HCPCS code E0779 and monitor for potential policy changes.
- New Product Adoption: Assess early sales data for the High-Flo® RMS Subcutaneous Needle Set following its May 2011 FDA approval.
- Debt Obligations: Review the repayment schedule for the $513,736 in long-term debt, noting the significant portion owed to a director.
- Related Party Transactions: Monitor ongoing lease payments for the aircraft and any future related-party financing arrangements.